Search Within

Marissa Mattar

  1. "Marc Ladanyi"
Formats
  1. Journal Article (16)
  2. Meeting Abstract (15)
  3. Research Letter (1)
Groups
  1. Department of Pathology and Laboratory Medicine (32)
  2. GSK Faculty (32)
  3. Human Oncology and Pathogenesis Program (32)
  4. Sloan Kettering Institute Postdocs (32)
  5. Tow Center for Developmental Oncology (TCDO) (32)
  6. Department of Medicine (20)

More Groups

People
  1. Marc Ladanyi (32)
  2. Romel Somwar (31)
  3. Elisa De Stanchina (27)
  4. Inna Khodos (23)
  5. Alexander Drilon (14)
  6. Igor Odintsov (13)

More People

Years
  1. 2025 (1)
  2. 2024 (4)
  3. 2023 (1)
  4. 2022 (10)
  5. 2021 (5)
  6. 2020 (3)

More Years

Publications
  1. Clinical Cancer Research (5)
  2. Journal of Thoracic Oncology (5)
  3. Cancer Research (4)
  4. Cancer Discovery (2)
  5. Disease Models & Mechanisms (2)
  6. European Journal of Cancer (2)

More Publications

Publishers
  1. American Association for Cancer Research (12)
  2. Elsevier Inc. (7)
  3. American Society of Clinical Oncology (3)
  4. Company of Biologists (2)
  5. Oxford University Press (2)
  6. Springer Nature (2)

More Publishers

Results (32)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Pan-cancer analysis of oncogenic MET fusions reveals distinct pathogenomic subsets with differential sensitivity to MET-targeted therapy
    Journal Article

    Febres-Aldana, C. A.; Vojnic, M.; Odintsov, I.; Zhang, T.; Cheng, R.; Beach, C. Z.; Lu, D.; Mattar, M. S.; Gazzo, A. M.; Gili, L.; more...
    Cancer Discovery (2025)

    Fulltext@MSK | Save
  • RRAS and RRAS2 mutations are oncogenic drivers in lung cancer and are sensitive to the PAN-RAS inhibitor RMC-6236
    Meeting Abstract

    Pfeil, A. J.; Zhang, T.; Febres-Aldana, C. A.; Cheng, R.; Mattar, M. S.; Arbour, K.; Ladanyi, M.; Yang, S. R.; Somwar, R.
    Journal of Thoracic Oncology (2024)

    Fulltext@MSK | Save
  • Comprehensive pan-cancer analysis of oncogenic MET rearrangements with a focus on targetability in NSCLC
    Meeting Abstract

    Vojnic, M.; Febres-Aldana, C. A.; Odintsov, I.; Zhang, T.; Beach, C. Z.; Lu, D.; Mattar, M. S.; Gazzo, A.; Gili, L.; Harshan, M.; more...
    Journal of Thoracic Oncology (2024)

    Fulltext@MSK | Save
  • Comprehensive pan-cancer analysis of oncogenic ERBB2 fusions
    Meeting Abstract

    Gomez Marti, J.; Zhang, T.; Febres Aldana, C.; Cheng, R.; Mattar, M.; Gili, L.; Master, R.; Liu, Z.; Ladanyi, M.; Somwar, R.
    Journal of Molecular Diagnostics (2024)

    Fulltext@MSK | Save
  • HER2 antibody-drug conjugates are active against desmoplastic small round cell tumor
    Journal Article

    Zhang, T.; Febres-Aldana, C. A.; Liu, Z.; Dix, J. M.; Cheng, R.; Dematteo, R. G.; Lui, A. J. W.; Khodos, I.; Gili, L.; Mattar, M. S.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations
    Journal Article

    Miyazaki, I.; Odintsov, I.; Ishida, K.; Lui, A. J. W.; Kato, M.; Suzuki, T.; Zhang, T.; Wakayama, K.; Kurth, R. I.; Cheng, R.; more...
    Nature Cancer (2023)

    Fulltext@MSK | Save
  • Prospective clinical genomic profiling of Ewing sarcoma: ERF and FGFR1 mutations as recurrent secondary alterations of potential biologic and therapeutic relevance
    Journal Article

    Ogura, K.; Elkrief, A.; Bowman, A. S.; Koche, R. P.; de Stanchina, E.; Benayed, R.; Mauguen, A.; Mattar, M. S.; Khodos, I.; Meyers, P. A.; more...
    JCO Precision Oncology (2022)

    Fulltext@MSK | Save
  • Tractable patient-derived models for preclinical therapeutic studies of CNS metastases
    Meeting Abstract

    Vojnic, M.; Odintsov, I.; Offin, M. D.; Lui, A. J. W.; Khodos, I.; Chang, Q.; Mattar, M. S.; De Stanchina, E.; Ladanyi, M.; Somwar, R.
    Neuro-Oncology (2022)

    Fulltext@MSK | Save
  • Vepafestinib is effective in preclinical models of sarcomas with RET fusion including a brain metastasis model
    Meeting Abstract

    Odintsov, I.; Liu, A.; Khodos, I.; Chang, Q.; Giuliano, C.; Mattar, M.; Vojnic, M.; Bonifacio, A.; De Stanchina, E.; Lovati, E.; more...
    European Journal of Cancer (2022)

    Fulltext@MSK | Save
  • MEK inhibitor resistance in lung adenocarcinoma is associated with addiction to sustained ERK suppression
    Journal Article

    Farnsworth, D. A.; Inoue, Y.; Johnson, F. D.; de Rappard-Yuswack, G.; Lu, D.; Shi, R.; Ma, L. I. J.; Mattar, M. S.; Somwar, R.; Ladanyi, M.; more...
    npj Precision Oncology (2022)

    Fulltext@MSK | Save